# Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)

> **NCT03945227** · PHASE2 · WITHDRAWN · sponsor: **Yonsei University**

## Conditions studied

- Stage III NSCLC

## Interventions

- **DRUG:** standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001
- **DRUG:** PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001

## Key facts

- **NCT ID:** NCT03945227
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the delay in the study shceduled, due to the start of competitive study and the approval of Durvalumab from the Ministry of Food and Drug Safety, it was judged that it was difficult to enroll subjects.
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945227, "Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03945227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*